Sumatriptan: Pharmacological Basis and Clinical Results

Carl G. H. Dahlöf

Disclosures

Curr Med Res Opin. 2001;17(1s) 

In This Article

Conclusions

The early promise shown by sumatriptan a decade ago when it was introduced as the first selective migraine therapy has been borne out in patient use. Sumatriptan advanced migraine therapy through its selective physiological action, which is realized in potent efficacy in the majority of patients and in a favourable side-effect profile. By virtue of its availability in four formulations, sumatriptan provides a mechanism for tailoring therapy to the individual patient and the individual migraine attack. Clinical data on sumatriptan continue to reveal new applications for sumatriptan, which has shown promise in treating non-migraine headaches in IHS-diagnosed migraineurs and in treating adolescent patients with migraine.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....